Dr Melania B Domingo, MD | |
510 Maple Dr, Vidalia, GA 30474-8912 | |
(912) 537-9334 | |
(912) 537-0019 |
Full Name | Dr Melania B Domingo |
---|---|
Gender | Female |
Speciality | Family Medicine |
Location | 510 Maple Dr, Vidalia, Georgia |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1740242023 | NPI | - | NPPES |
000014671A | Medicaid | GA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 017919 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Melania B Domingo, MD 510 Maple Dr, Vidalia, GA 30474-8912 Ph: (912) 537-9334 | Dr Melania B Domingo, MD 510 Maple Dr, Vidalia, GA 30474-8912 Ph: (912) 537-9334 |
News Archive
SonoSite, Inc., the world leader and specialist in bedside and point-of-care ultrasound, today announced that it has signed an agreement to acquire privately held Visualsonics, a Toronto-based company focused on ultra high-frequency micro-ultrasound technology. The aggregate transaction value will be approximately $71 million net of cash and debt.
Jean-François Côté, a researcher at the Montreal Clinical Research Institute and professor at Université de Montréal's Faculty of Medicine, studies metastasis, the leading cause of cancer-related death. Recently, his team uncovered a protein that, once deactivated, could prevent the development of metastases in an aggressive type of cancer, HER2-positive breast cancer.
The National Institute of Mental Health has signed an agreement to establish a collaborative, nationwide effort for the collection, storage, and distribution of postmortem human brain tissue for the benefit of autism research. The agreement with Foundation Associates LLC will coordinate the efforts of two independent networks of human brain tissue repositories, the National Institutes of Health NeuroBioBank and the Autism BrainNet.
Lux Biosciences, Inc. today announced the completion of patient enrollment in its Phase 3 clinical study of Luveniq (oral voclosporin) for the treatment of non-infectious uveitis. Lux Biosciences anticipates that data from the Phase 3 study will be available early in the first quarter of 2013.
› Verified 6 days ago